<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joy D Howell, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrienne G Randolph, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Asthma is the most frequent cause of hospitalization among children in the United States and is the source of nearly 500,000 admissions to pediatric intensive care units (PICUs) [<a href="#rid1">1</a>]. Admission to intensive care has increased in proportion to general hospital admission for asthma [<a href="#rid2">2</a>]. Mortality rates in children are lower than adults, but males and African Americans have a higher risk for death compared with girls and white Americans.</p><p>Intensive care unit (ICU) management of children with acute severe asthma exacerbation (ie, status asthmaticus) is discussed here, with the exception that endotracheal intubation and mechanical ventilation are discussed separately. Non-ICU inpatient management is also discussed in detail separately. Mechanical ventilation for adults with severe asthma is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"</a> and  <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Inpatient management"</a> and  <a class="medical medical_review" href="/z/d/html/570.html" rel="external">"Invasive mechanical ventilation in adults with acute exacerbations of asthma"</a>.)</p><p>Pharmacologic management of acute asthma exacerbations and management of chronic childhood asthma also are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a> and  <a class="medical medical_review" href="/z/d/html/5742.html" rel="external">"Asthma in children younger than 12 years: Initial evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5744.html" rel="external">"Asthma in children younger than 12 years: Management of persistent asthma with controller therapies"</a> and  <a class="medical medical_review" href="/z/d/html/5743.html" rel="external">"Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The pathologic hallmarks of asthma are airway inflammation, excessive mucus production, mucus plugging, and airway bronchospasm, all of which may lead to severe airflow obstruction. Airflow obstruction produces varying degrees of respiratory insufficiency and can progress to respiratory failure. Both the severity of the exacerbation and presence of risk factors associated with the need for ICU management are taken into account when admitting a child with an acute asthma exacerbation.</p><p class="headingAnchor" id="H524285346"><span class="h2">Severity assessment</span><span class="headingEndMark"> — </span>Severe acute asthma is somewhat loosely defined based upon presenting signs and symptoms and response to therapy  (<a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">table 1</a>). There are several scoring systems to help assess asthma severity in children. Examples include the Pulmonary Index Score  (<a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">table 2</a>) [<a href="#rid3">3</a>] and the Pulmonary Score, which is similar to the Pulmonary Index Score except that it scores only respiratory rate, wheezing, and accessory muscle use [<a href="#rid4">4</a>]. Another is the Pediatric Intensive Care Unit Pediatric Asthma Score, which factors in respiratory rate relative to age, oxygen requirement, presence of retractions, breathlessness during speech, and presence of wheezing [<a href="#rid5">5</a>]. The assessment of severity of acute asthma exacerbations is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Assessment of exacerbation severity'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Boys, children living in poverty, African Americans, and some Hispanics (especially Puerto Ricans) have high rates of asthma and severe asthma. Patients who are at risk for requiring ICU management for asthma include those who have a history of [<a href="#rid6">6-13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>ICU admissions, mechanical ventilation, or rapidly progressive and sudden respiratory deterioration</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures or syncope during an asthma exacerbation</p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbations precipitated by food</p><p class="bulletIndent1"><span class="glyph">●</span>Use of more than two beta-agonist metered-dose inhaler (MDI) canisters per month</p><p class="bulletIndent1"><span class="glyph">●</span>Insufficient controller therapy or poor adherence to controller therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Denial of or failure to appreciate the severity of illness</p><p class="bulletIndent1"><span class="glyph">●</span>Associated depression or other psychiatric disorder</p><p></p><p>Although these factors are frequently present in patients who require ICU management, they fail to prospectively identify a significant number of cases [<a href="#rid6">6</a>] and should not be interpreted as absolute indications for admission to an ICU. As many as one-third of children who die from asthma would not have been classified as at risk for fatal asthma based upon these risk factors. Risk factors for fatal asthma are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/565.html" rel="external">"Identifying patients at risk for fatal asthma", section on 'Identifying high-risk patients'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Children with acute severe asthma who fail to improve with initial treatment in the emergency department should be admitted to the pediatric ICU (PICU). ICU level management of these children entails the administration of glucocorticoids, aggressive bronchodilator therapy, and close monitoring [<a href="#rid5">5</a>]. Mechanical ventilation is reserved for patients with continued progression toward respiratory failure despite maximal medical therapy. (See <a class="local">'Pharmacotherapy'</a> below and  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"</a>.)</p><p>The need for mechanical ventilation should be considered early in the course of illness. Mechanical ventilation in a child with an asthma exacerbation is always challenging, usually due to airway obstruction and difficulty with exhalation. The best way to avoid intubation is to rapidly escalate the preintubation therapies discussed below in patients with a worsening trajectory indicated by increased work of breathing or carbon dioxide (CO<sub>2</sub>) retention. The decision to intubate a patient should be made with great care since tracheal stimulation often worsens the asthma exacerbation and, in some cases, makes the situation worse.</p><p>In many patients who are progressing toward respiratory muscle fatigue, noninvasive positive pressure ventilation (NPPV) can avoid the need for intubation by easing the work of breathing while awaiting the maximal therapeutic effects of pharmacotherapy. NPPV in conjunction with pharmacologic therapy is effective in improving gas exchange in children and adults with asthma. NPPV can be used in school-aged children with relative ease, but light sedation may be required to facilitate tolerance in younger children [<a href="#rid5">5</a>]. (See <a class="local">'Noninvasive positive pressure ventilation'</a> below.)</p><p>Adjunctive therapies may be necessary for children who do not improve despite aggressive pharmacologic therapy and mechanical ventilation. (See <a class="local">'Adjunctive therapies'</a> below and  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Adjunctive therapies'</a>.)</p><p>There are no widely used, evidence-based treatment algorithms or pathways for the management of acute severe asthma in children, and there is considerable variability in care. The use of an algorithm for escalation and weaning of therapy was applied to 385 children older than two years of age with status asthmaticus admitted on continuous <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> to the medical ICU of one center [<a href="#rid14">14</a>]. The use of this protocol was associated with a decrease in the duration of continuous albuterol therapy and reduced length of hospital stay. Although the findings require replication in other centers, standardized-care protocols could improve outcomes in the future.</p><p class="headingAnchor" id="H6"><span class="h1">PREINTUBATION THERAPIES</span><span class="headingEndMark"> — </span>The primary preintubation therapies are supplemental oxygen, glucocorticoids, bronchodilators, inhaled anticholinergics, and systemic <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> [<a href="#rid15">15</a>]. Noninvasive positive pressure ventilation (NPPV) may help to avoid endotracheal intubation in select patients who continue to have severe or unabated increased work of breathing while awaiting the maximum therapeutic benefit of pharmacotherapy. It is important to determine whether the inhaled bronchodilators can be delivered via the noninvasive ventilation device since this is often not the case and intravenous bronchodilators can be started.</p><p class="headingAnchor" id="H7"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>The goal of pharmacologic therapy for acute severe asthma exacerbations is to ensure adequate oxygenation and ventilation and ease the work of breathing. Pharmacologic therapy of children who are admitted to the ICU with acute severe asthma exacerbation entails the administration of glucocorticoids and aggressive bronchodilator therapy  (<a class="graphic graphic_algorithm graphicRef52015" href="/z/d/graphic/52015.html" rel="external">algorithm 1</a>). We recommend the administration of intravenous glucocorticoids and inhaled <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a>. We also suggest inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a> and intravenous <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> if the patient was not already treated with these medications.</p><p>For those who fail to respond to these interventions, we suggest the administration of parenteral beta<sub>2</sub>-agonists. The efficacy of these interventions has been documented in meta-analyses and/or randomized, controlled trials, which are described separately. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Severe exacerbation'</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Elements of treatment'</a>.)</p><p class="headingAnchor" id="H1105464426"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are usually administered intravenously in children who are admitted to the ICU with acute asthma exacerbation.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">Methylprednisolone</a> (loading dose 2 mg/kg, then 0.5 to 1 mg/kg/dose every six hours, with a maximum dose of 60 mg/day) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Management of inflammation'</a>.)</p><p></p><p class="headingAnchor" id="H1105464432"><span class="h3">Bronchodilators</span><span class="headingEndMark"> — </span>The primary bronchodilator therapy is inhaled <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a>. Inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a> bromide and intravenous <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> are adjunctive therapies that are often also used because they have been shown to decrease the risk of hospitalization for children treated in the emergency department. They have not been shown to offer further benefit in hospitalized patients, but they have not been studied in the pediatric ICU (PICU) population [<a href="#rid5">5</a>]. Additional intravenous bronchodilators may be used in patients who do not respond to initial bronchodilatory therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>Hourly or continuously delivered <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> via nebulizer (see  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled short-acting beta-2 agonists'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For hourly administration, <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> (0.15 mg/kg every hour, minimum 2.5 mg; maximum 5 mg), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For continuous administration, <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> (10 mg/hour for children who weigh 5 to 10 kg, 15 mg/hour for children who weigh 10 to 20 kg, and 20 mg/hour for children who weigh &gt;20 kg). Alternatively, continuous albuterol can be dosed 0.15 to 0.5 mg/kg/hour, up to a maximum dose of 30 mg/hour [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">Magnesium sulfate</a> (25 to 75 mg/kg intravenously; maximum 2 grams) is administered over 20 to 30 minutes upon arrival to the ICU if it has not been administered earlier. Patients should be monitored for hypotension, especially if they have received <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a> and are vasodilated, although this complication is rare [<a href="#rid17">17</a>]. If hypotension does occur, the magnesium sulfate infusion should be paused, a fluid bolus administered, and then the infusion resumed at a lower rate [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Magnesium sulfate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of benefit for <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a><strong> bromide</strong> has not been demonstrated in hospitalized patients, and, therefore, it is not recommended for hospitalized patients by the National Heart Lung and Blood Institute (NHLBI) asthma guidelines [<a href="#rid19">19</a>]. However, it has not yet been specifically studied in the PICU population, and one review found no trials reporting any serious adverse events associated with its use [<a href="#rid20">20</a>]. Thus, some experts will use ipratropium bromide as an adjunctive therapy in hospitalized children with impending respiratory failure due to asthma who fail to respond to the usual therapies. A dosing regimen extrapolated from management of children with chronic lung disease can be used in a child with severe status asthmaticus and impending respiratory failure (250 microgram per dose every 6 hours for 24 hours for children who weigh &lt;20 kg or ≤6 years of age; 500 microgram per dose every 6 hours for 24 hours for children who weigh &gt;20 kg or ≥6 years of age) [<a href="#rid5">5,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Ipratropium bromide'</a>.)</p><p></p><p>For patients who fail to respond to the bronchodilator therapy reviewed above, we suggest the transition to intravenous bronchodilators [<a href="#rid22">22,23</a>]. <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">Terbutaline</a> is most commonly used. <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">Theophylline</a> and <a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">aminophylline</a> (the water-soluble, ethylenediamine salt of theophylline), methylxanthines with phosphodiesterase inhibitor activity, were historically a standard component of acute asthma management but over the past 30 years have essentially been eliminated from standard treatment algorithms for acute asthma. Evidence in support of their use in the inpatient population is limited at best. Thus, these agents are infrequently used in PICUs for status asthmaticus. However, we reserve aminophylline as an option for the child with severe status asthmaticus and impending respiratory failure who has not responded to terbutaline. Extreme caution should be employed in the patient with risk factors for myocardial ischemia since tachycardia increases myocardial oxygen demand. In addition, children who present with status asthmaticus are predisposed to dehydration/intravascular depletion. Thus, fluid loading may be necessary to blunt some of the tachycardia associated with use of intravenous bronchodilators. (See <a class="local">'Fluid support'</a> below and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Parenteral beta-agonists'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">Terbutaline</a> (10 microgram/kg intravenous loading dose administered over 10 minutes, followed by an infusion of 0.1 to 10 microgram/kg/minute). The dosing range found in most references for intravenous terbutaline is remarkably wide. Although dosing as low as 0.1 microgram/kg/minute are suggested, experienced intensivists usually begin with a dose of 0.5 micrograms/kg/minute. The infusion can be increased in 0.1 to 1 microgram/kg/minute increments every 30 minutes, depending upon the patient's degree of respiratory distress, heart rate, perfusion, and quality of aeration, to a maximum dose of 5 to 10 micrograms/kg/minute (the author rarely exceeds a dose of 3 to 5 micrograms/kg/minute) until aeration and work of breathing improve. Continuous <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> should be discontinued once terbutaline is initiated.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">Terbutaline</a> causes tachycardia and, in turn, increases myocardial oxygen consumption. In general, the younger the age, the better tachycardia is tolerated. At the author's center, patients with severe status asthmaticus requiring terbutaline infusion receive fluid boluses in an effort to blunt some of the tachycardia. Serial troponin levels and electrocardiograms are sometimes obtained, particularly in adolescent and preadolescent patients on both terbutaline and <a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">aminophylline</a> infusions, to monitor for evidence of myocardial ischemia. Terbutaline infusions may be associated with hypotension, hyperglycemia, hypokalemia, and arrhythmias [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">Aminophylline</a> (6 mg/kg intravenous loading dose, followed by infusion of 0.5 to 1 mg/kg/hour that is titrated based upon levels). The recommended starting dose of the infusion (after the loading dose) varies by age for patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>6 weeks to 6 months – 0.5 mg/kg/hour</p><p class="bulletIndent2"><span class="glyph">•</span>6 to 12 months – 0.6 to 0.7 mg/kg/hour</p><p class="bulletIndent2"><span class="glyph">•</span>1 to 9 years – 1 mg/kg/hour</p><p class="bulletIndent2"><span class="glyph">•</span>9 to 16 years – 0.8 mg/kg/hour</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">Aminophylline</a> has a mean volume of distribution of 0.5 L/kg. Thus, a loading dose of 6 mg/kg should generate a serum level of approximately 12 microgram/mL. Therapeutic levels range between 10 and 20 microgram/mL. We suggest target levels of 12 to 15 microgram/mL, particularly upon initiation of therapy. Steady-state levels are checked 6 to 12 hours following the bolus/initiation of the infusion. If the patient's respiratory status does not improve and the six-hour <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">theophylline</a> level is below 15 microgram/mL, then the infusion is increased proportionately to a target level of 15 microgram/mL. Serum levels of aminophylline should be measured once daily (after desired level or response to therapy achieved) and as needed when toxicity is suspected (severe tachycardia, anxiety, persistent emesis, dysrhythmias, and seizures).</p><p></p><p class="bulletIndent1">A review published in 2005 explored the efficacy of <a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">aminophylline</a> in children with acute severe asthma [<a href="#rid24">24</a>]. Improvement in lung function within six hours was demonstrated, but there was no apparent reduction in the number of nebulized treatments given or length of hospital stay. There was insufficient evidence to assess its impact on oxygenation, PICU admissions, and mechanical ventilation. One randomized trial compared <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a>, <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">theophylline</a>, and combination therapy with both drugs in a cohort of PICU patients [<a href="#rid23">23</a>]. Theophylline was as effective as terbutaline in treating critically ill children with asthma and was more cost effective. Despite the lack of consistent evidence of benefit and the fact that aminophylline is not recommended by National Asthma Education and Prevention Program (NAEPP) guidelines, 59 percent of respondents to a survey administered to pediatric critical care medicine fellowship program directors (academic intensivists), reported using aminophylline for children with severe status asthmaticus refractory to other therapies [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/560.html" rel="external">"Theophylline use in asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> is not available in the United States. However, in countries where it is available, efficacy in patients with acute severe asthma has been demonstrated in randomized and observational studies [<a href="#rid26">26,27</a>]. The dose is 0.5 to 5 microgram/kg/minute [<a href="#rid27">27</a>]. Subcutaneous or intramuscular <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> or <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a> are additional options if intravenous terbutaline is not available [<a href="#rid19">19</a>]. Dosing for subcutaneous or intramuscular epinephrine is 0.01 mg/kg (0.01 mL/kg of 1:1000 solution [1 mg/mL]) every 20 minutes for up to three doses, maximum dose 0.5 mg. Dosing of subcutaneous or intramuscular terbutaline is 0.01 mg/kg (0.01 mL/kg of a 1 mg/mL solution) every 20 minutes for up to three doses and then every two to six hours as needed, maximum dose 0.25 mg.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Noninvasive positive pressure ventilation</span><span class="headingEndMark"> — </span>NPPV eases the work of breathing in patients who are progressing toward respiratory muscle fatigue. Thus, NPPV may help to avoid endotracheal intubation in select patients who continue to have severe or unabated symptoms after intravenous bronchodilators or while awaiting the maximum therapeutic benefit of pharmacotherapy. NPPV has been used to treat children with respiratory failure from a number of causes, including neuromuscular disorders, cystic fibrosis, bronchiolitis, and status asthmaticus [<a href="#rid28">28-40</a>]. The benefits for children with status asthmaticus are thus far favorable, with retrospective and prospective studies documenting clinical improvement in the pediatric emergency department and ICU settings [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">"Noninvasive ventilation for acute and impending respiratory failure in children"</a>.)</p><p>NPPV involves the delivery of positive airway pressure, either as continuous pressure (continuous positive airway pressure [CPAP]) or as mechanically assisted breaths (bilevel positive airway pressure [BiPAP]), without placement of an artificial airway. In most cases, ventilation is delivered via full facial mask. Patients who receive NPPV must be awake and cooperative, have a patent airway, and have spontaneous respirations. Toddlers and small children may require mild sedation to tolerate the mask. (See  <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">"Noninvasive ventilation for acute and impending respiratory failure in children"</a>.)</p><p class="headingAnchor" id="H1105465750"><span class="h3">Mechanisms of action of NPPV</span><span class="headingEndMark"> — </span>NPPV may be useful as a temporizing measure while awaiting the maximal therapeutic benefit of pharmacotherapy and may help patents avoid the need for intubation. During an asthma attack, bronchospasm and increased mucus production result in airflow obstruction in the distal airways that cause increased airway resistance and development of long expiratory time constants in lung units. This leads to the development of air trapping and dynamic hyperinflation, also known as auto-PEEP. The development of auto-PEEP necessitates an increase in the work of breathing since a greater negative force must be generated for inspiration to begin in the context of air trapping. NPPV may improve this phenomenon by stenting open collapsing or narrowed airways, thereby allowing for more complete exhalation. This in turn reduces the inspiratory work of breathing. Additionally, the application of inspiratory positive airway pressure (IPAP) further unloads the muscles of respiration [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">"Noninvasive ventilation for acute and impending respiratory failure in children", section on 'Physiology'</a>.)</p><p class="headingAnchor" id="H1105465781"><span class="h3">Efficacy of NPPV</span><span class="headingEndMark"> — </span>Evidence supporting the benefit of NPPV in children with acute severe asthma is accruing, although further trials are still needed [<a href="#rid42">42</a>].</p><p>The safety, efficacy, and tolerability of BiPAP in children admitted to the PICU with status asthmaticus was evaluated in a randomized trial of standard therapy versus standard therapy plus NPPV for 24 hours [<a href="#rid43">43</a>]. The outcome measures included change in clinical asthma score, respiratory rate, oxygen saturation, and oxygen requirement. Adjunctive therapies could be employed, at the discretion of the attending clinician, only if patients experienced an increase in their clinical asthma score beyond two hours after enrollment. Rapid and significant improvements in clinical asthma score were reported at each time point studied, although no significant differences between the two groups were seen for the other outcome measures. NPPV was well tolerated, and no major complications were reported.</p><p>In a prospective study, 20 children (median age 4.8 years) admitted to the PICU with acute lower airway obstruction were randomly assigned to two hours of NPPV followed by two hours of standard therapy or to two hours of standard therapy followed by two hours of NPPV [<a href="#rid36">36</a>]. Compared with standard therapy, NPPV decreased respiratory rate, accessory muscle use, and dyspnea. No serious morbidity was noted, but five patients were unable to tolerate NPPV for the duration of the study.</p><p>In several observational studies and case series, treatment with NPPV was associated with improved clinical and ventilatory parameters in children with asthma [<a href="#rid34">34,35,37,40,44,45</a>]. A reduction in PICU admissions was reported when BiPAP was used in the pediatric emergency department setting [<a href="#rid37">37</a>]. However, four of five patients in one of the smallest case series were morbidly obese (body mass index ≥30). Thus, the improvement in their respiratory status with NPPV may have been related to underlying obesity hypoventilation syndrome, although none of them reported a previous history [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"</a>.)</p><p class="headingAnchor" id="H524286211"><span class="h3">Possible indications for NPPV</span><span class="headingEndMark"> — </span>The use of NPPV in children with status asthmaticus varies from center to center. We suggest a trial of NPPV in the following situations, provided that the child is alert, cooperative, and without increased airway secretions:</p><p class="bulletIndent1"><span class="glyph">●</span>The child remains hypoxemic despite high flow oxygen and/or has documented hypercarbia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The child is progressing toward respiratory muscle fatigue, but the maximum therapeutic effects of glucocorticoids and bronchodilators have not been reached.</p><p></p><p class="headingAnchor" id="H524286217"><span class="h3">Limitations of NPPV</span><span class="headingEndMark"> — </span>The use of NPPV is limited because it:</p><p class="bulletIndent1"><span class="glyph">●</span>Requires patient cooperation</p><p class="bulletIndent1"><span class="glyph">●</span>Impairs ability to clear secretions from the respiratory tract</p><p class="bulletIndent1"><span class="glyph">●</span>Does not provide definitive control of the airway</p><p class="bulletIndent1"><span class="glyph">●</span>May cause gastric distension with increased risk of aspiration</p><p class="bulletIndent1"><span class="glyph">●</span>May cause heightened sense of air hunger upon initiation</p><p class="bulletIndent1"><span class="glyph">●</span>Patients may feel claustrophobic</p><p></p><p>An experienced nurse or respiratory therapist who can coach the patient through the initiation of NPPV is invaluable. Mild sedatives are sometimes used to facilitate the patient's tolerance of NPPV [<a href="#rid35">35</a>], but great care must be taken to avoid diminishing airway protective reflexes and respiratory drive.</p><p class="headingAnchor" id="H524286233"><span class="h3">NPPV settings</span><span class="headingEndMark"> — </span>NPPV can begin as CPAP with a pressure of 5 cm H<sub>2</sub>O in patients with moderately increased work of breathing  (<a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">table 1</a>) or relatively mild-moderate degrees of hypoxemia (those who can maintain oxygen saturation greater than 92 percent with the provision of simple face mask oxygen at fraction of inspired oxygen [FiO<sub>2</sub>] of 0.25 to 0.7) or hypercarbia (partial pressure of carbon dioxide in arterial blood [PaCO<sub>2</sub>] of 45 to 50 mmHg).</p><p>BiPAP provides a greater level of support and decreases the work of breathing more efficiently in patients with significantly increased work of breathing and moderate or severe hypoxemia (patients requiring FiO<sub>2</sub> &gt;70 percent by simple face mask or nonrebreather mask) and/or hypercarbia (PaCO<sub>2</sub> &gt;50 mmHg). The initial BiPAP settings should be relatively low and should be titrated to patient comfort, oxygenation, and ventilation. The inspiratory pressure may start at 8 to 10 cm H<sub>2</sub>O and the expiratory pressure at 5 cm H<sub>2</sub>O. These settings may be titrated up to an inspiratory pressure of 10 to 12 cm H<sub>2</sub>O, and the expiratory pressure may be carefully titrated up to 7 to 8 cm H<sub>2</sub>O.</p><p class="headingAnchor" id="H89210977"><span class="h2">High-flow nasal cannula</span><span class="headingEndMark"> — </span>High-flow nasal cannula (HFNC) is becoming widely available in patients with respiratory embarrassment from a variety of sources including status asthmaticus. There is sparse literature evaluating the use of HFNC specifically in children with status asthmaticus. In a single-center retrospective study evaluating the use of HFNC in children with status asthmaticus, investigators demonstrated the safety and feasibility of HFNC in this setting, with rare instances of treatment failure (progression to NPPV or intubation) and pneumothorax [<a href="#rid46">46,47</a>].</p><p class="headingAnchor" id="H1105464578"><span class="h2">Heliox</span><span class="headingEndMark"> — </span>Heliox is supplied in fixed gas mixtures 20 percent oxygen and 80 percent helium so that hypoxic gas mixtures are not inadvertently administered to patients. Additional oxygen can be blended and the oxygen concentration measured proximal to the patient. The physiochemical principles of heliox increase laminar flow, as well as lower viscosity, compared with nitrogen and oxygen. However, concentrations of oxygen &gt;40 percent limit the beneficial effects of helium.</p><p>There are limited and conflicting data regarding the efficacy of heliox in the treatment of children with acute severe asthma [<a href="#rid48">48</a>]. Clinical improvement based upon a pulmonary index score was reported in a small, prospective study of heliox-driven nebulizer treatments [<a href="#rid49">49</a>]. A subsequent review concluded that heliox may have a role in the initial management of asthma in patients with more severe obstruction based upon available data from a series of small studies [<a href="#rid50">50</a>]. Use of heliox is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/541.html" rel="external">"Physiology and clinical use of heliox", section on 'Use in children'</a>.)</p><p class="headingAnchor" id="H344207426"><span class="h1">INTUBATION AND MECHANICAL VENTILATION</span><span class="headingEndMark"> — </span>Mechanical ventilation is reserved for patients with continued progression toward respiratory failure despite maximal medical therapy. Endotracheal intubation should be approached cautiously in patients with status asthmaticus because manipulation of the airway can cause increased airflow obstruction due to exaggerated bronchial responsiveness. Intubation and mechanical ventilation are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation"</a>.)</p><p>Indications for endotracheal intubation and mechanical ventilation include (see  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Indications'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia</p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status, including agitation and obtundation</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent, severe hypercarbia</p><p></p><p class="headingAnchor" id="H1105464739"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Children admitted to the ICU with severe asthma require close cardiopulmonary monitoring, particularly those on mechanical ventilation. Supportive measures for children with asthma who require mechanical ventilation include analgesia, sedation, and muscle relaxation [<a href="#rid6">6</a>]. These measures help to prevent tachypnea, breath stacking, and ventilator dyssynchrony, particularly in the setting of hypercapnia. Most patients are also given intravenous fluids to treat dehydration and prevent hypotension. Sedation and paralysis are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Sedation and paralysis'</a>.)</p><p class="headingAnchor" id="H1105464770"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Children who are admitted to the ICU for management of acute severe asthma are usually monitored with a cardiorespiratory monitor that displays a continuous electrocardiogram tracing, noninvasive blood pressure, oxygen saturation, and respiratory rate [<a href="#rid6">6</a>].</p><p>Additional monitoring includes frequent auscultation. Auscultation provides important information regarding aeration, optimal duration of exhalation (wheezing should terminate before the onset of the next inhalation), and the presence of pneumothorax or mucus plugging (indicated by asymmetric breath sounds) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1105464836"><span class="h2">Fluid support</span><span class="headingEndMark"> — </span>The fluid status of children with acute severe asthma exacerbation who are admitted to the ICU must be carefully monitored. Many patients are hypovolemic on presentation (related to poor intake and increased insensible fluid loss from the respiratory tract) [<a href="#rid6">6</a>]. The risk of hypotension is increased in patients who are mechanically ventilated and who receive sedatives and paralytics. Intravenous fluids should be administered to replace losses and optimize intravascular volume. However, overhydration should be avoided since it may result in pulmonary edema. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Hypotension'</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">ADJUNCTIVE THERAPIES</span><span class="headingEndMark"> — </span>In extreme cases, airflow obstruction is so severe that sufficient ventilation cannot be achieved despite intensive bronchodilator therapy, intravenous glucocorticoids, ventilatory support, sedation, and paralysis. In such cases, adjunctive therapies, such as inhalational anesthetics or extracorporeal membrane oxygenation (ECMO), may be successful as rescue measures. However, the routine use of these therapies cannot be recommended on the basis of existing clinical studies. They remain heroic rescue maneuvers for the extremely refractory patient. These therapies are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Adjunctive therapies'</a>.)</p><p class="headingAnchor" id="H608056946"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications can result from the asthma exacerbation itself or the treatments. Patients with an acute severe asthma exacerbation are at risk for progressive air trapping and alveolar hyperinflation, which may lead to alveolar rupture and hemodynamic compromise. Endotracheal intubation with mechanical ventilation in the child with asthma can be associated with significant morbidity including hypotension, barotrauma (including pneumothorax), and myopathy. These and other complications are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H608058861"><span class="h1">STEPPING DOWN THERAPIES</span><span class="headingEndMark"> — </span>Interventions should gradually be weaned as the patient improves.</p><p class="headingAnchor" id="H608055764"><span class="h2">Discontinuing noninvasive positive pressure ventilation</span><span class="headingEndMark"> — </span>Bilevel positive airway pressure (BiPAP) can be weaned to continuous positive airway pressure (CPAP) when the patient's work of breathing and respiratory rate are minimally elevated  (<a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">table 1</a>) and the oxygen requirement is &lt;50 percent. CPAP can be withdrawn when the work of breathing and respiratory rate have normalized and the oxygen requirement is ≤40 percent.</p><p class="headingAnchor" id="H608058905"><span class="h2">Weaning medications</span><span class="headingEndMark"> — </span>In the absence of evidenced-based guidelines for many of the adjunctive therapies contained in this topic review, we must acknowledge that clinical judgment and local practice patterns often dictate how patients are weaned from intravenous bronchodilator therapy. More important than the precise order in which medications are discontinued is the careful monitoring of the patient as therapy is withdrawn. Patients treated with intravenous <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a> should have the medication weaned to 0.5 to 1 mcg/kg/minute once clinical improvement is demonstrated and from there may be transitioned to continuous nebulized <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> with one hour of overlapping therapy. Thereafter, they may be weaned to hourly nebulizer treatments as tolerated. Although not evidenced based, at the author's institution, if <a class="drug drug_pediatric" data-topicid="12572" href="/z/d/drug information/12572.html" rel="external">aminophylline</a> is employed, it is generally continued until patients are consistently tolerating intermittent inhaled albuterol at a frequency of every one to two hours.</p><p class="headingAnchor" id="H608058919"><span class="h1">CRITERIA FOR TRANSFER OUT OF THE ICU</span><span class="headingEndMark"> — </span>Criteria for transitioning patients from the pediatric ICU (PICU) to the general pediatric ward undoubtedly vary among institutions and are largely a matter of clinical judgment. However, several general criteria are useful to consider when making this decision, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Successful weaning from invasive or noninvasive positive pressure ventilation (NPPV)</p><p class="bulletIndent1"><span class="glyph">●</span>Successful weaning/cessation of intravenous bronchodilators</p><p class="bulletIndent1"><span class="glyph">●</span>Requirement of aerosolized bronchodilators at a frequency that can be safely delivered on the general pediatric ward</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen requirement within the range of what can be safely and locally appropriate to deliver on the general pediatric ward</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary monitoring needs within the range of what can be safely delivered on the general pediatric ward</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal increased work of breathing</p><p></p><p class="headingAnchor" id="H33"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>While overall mortality is low (0.5 percent in one survey [<a href="#rid51">51</a>]), patients with status asthmaticus who require mechanical ventilation have increased in-hospital mortality compared with patients who do not require mechanical ventilation. Outcomes in ventilated patients are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Outcomes'</a>.)</p><p>Patients who have required an ICU admission for an asthma exacerbation are at risk for having another life-threatening or fatal asthma exacerbation. Thus, they should be closely followed by an asthma specialist in the outpatient setting.</p><p class="headingAnchor" id="H2877033648"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113453.html" rel="external">"Society guideline links: Asthma in children"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for admission to PICU</strong> – An acute severe asthma exacerbation is somewhat loosely defined based upon presenting signs and symptoms and response to therapy (eg, a Pulmonary Index Score of ≥12  (<a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">table 2</a>) or peak flow rate &lt;40 percent of the predicted value for age, sex, and height or personal best  (<a class="graphic graphic_table graphicRef76344" href="/z/d/graphic/76344.html" rel="external">table 1</a>)). Children with an acute severe asthma exacerbation who fail to improve with initial treatment in the emergency department should be admitted to the pediatric intensive care unit (PICU). (See <a class="local">'Overview'</a> above and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to pharmacotherapy</strong> – Intensive care unit (ICU) management of children with acute severe asthma entails aggressive pharmacotherapy. We recommend the administration of intravenous glucocorticoids and inhaled <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>), and we suggest the administration of inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) and intravenous <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). For patients who fail to respond to these measures, we suggest the administration of parenteral beta<sub>2</sub>-agonists (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Pharmacotherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Elements of treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive positive pressure ventilation</strong> – In select patients, noninvasive positive pressure ventilation (NPPV) may avoid the need for intubation. We suggest a trial of NPPV in the following situations, provided that the child is alert, cooperative, and without increased airway secretions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Noninvasive positive pressure ventilation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The child remains hypoxemic despite high-flow oxygen and/or has documented hypercarbia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The child is progressing toward respiratory muscle fatigue, but the maximum therapeutic effects of glucocorticoids and bronchodilators have not been reached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and fluid support</strong> – Children admitted to the ICU with severe asthma require close cardiopulmonary monitoring. Most patients are also given intravenous fluids to treat dehydration and prevent hypotension. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stepping down therapies</strong> – Interventions should gradually be weaned as the patient improves. More important than the precise order in which medications are discontinued is the careful monitoring of the patient as therapy is withdrawn. (See <a class="local">'Stepping down therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Overall mortality in children with acute severe asthma exacerbations is approximately 0.5 percent. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ 2002; 51:1.</a></li><li><a class="nounderline abstract_t">Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in admissions for pediatric status asthmaticus in New Jersey over a 15-year period. Pediatrics 2010; 126:e904.</a></li><li><a class="nounderline abstract_t">Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.</a></li><li><a class="nounderline abstract_t">Smith SR, Strunk RC. Acute asthma in the pediatric emergency department. Pediatr Clin North Am 1999; 46:1145.</a></li><li><a class="nounderline abstract_t">Nievas IF, Anand KJ. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther 2013; 18:88.</a></li><li class="breakAll">Rotta AT. Asthma. In: Pediatric critical care, 3rd ed, Fuhrman BP, Zimmerman JJ (Eds), Mosby, Philadelphia 2006. p.589.</li><li><a class="nounderline abstract_t">Chipps BE, Murphy KR. Assessment and treatment of acute asthma in children. J Pediatr 2005; 147:288.</a></li><li><a class="nounderline abstract_t">Strunk RC, Mrazek DA, Fuhrmann GS, LaBrecque JF. Physiologic and psychological characteristics associated with deaths due to asthma in childhood. A case-controlled study. JAMA 1985; 254:1193.</a></li><li><a class="nounderline abstract_t">Kolbe J, Vamos M, Fergusson W, Elkind G. Determinants of management errors in acute severe asthma. Thorax 1998; 53:14.</a></li><li><a class="nounderline abstract_t">Ordoñez GA, Phelan PD, Olinsky A, Robertson CF. Preventable factors in hospital admissions for asthma. Arch Dis Child 1998; 78:143.</a></li><li><a class="nounderline abstract_t">Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82:59.</a></li><li><a class="nounderline abstract_t">Triasih R, Duke T, Robertson CF. Outcomes following admission to intensive care for asthma. Arch Dis Child 2011; 96:729.</a></li><li><a class="nounderline abstract_t">Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J 2015; 45:396.</a></li><li><a class="nounderline abstract_t">Melendez E, Dwyer D, Donelly D, et al. Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus. Pediatr Crit Care Med 2020; 21:451.</a></li><li class="breakAll">From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/ (Accessed on November 07, 2014).</li><li><a class="nounderline abstract_t">Giuliano JS Jr, Faustino EV, Li S, et al. Corticosteroid therapy in critically ill pediatric asthmatic patients. Pediatr Crit Care Med 2013; 14:467.</a></li><li><a class="nounderline abstract_t">DeSanti RL, Agasthya N, Hunter K, Hussain MJ. The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting. Pediatr Pulmonol 2018; 53:866.</a></li><li><a class="nounderline abstract_t">Pardue Jones B, Fleming GM, Otillio JK, et al. Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit. J Asthma 2016; 53:607.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 1, 2007).</li><li><a class="nounderline abstract_t">Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev 2014; :CD010283.</a></li><li><a class="nounderline abstract_t">Roberts JS, Bratton SL, Brogan TV. Acute severe asthma: differences in therapies and outcomes among pediatric intensive care units. Crit Care Med 2002; 30:581.</a></li><li><a class="nounderline abstract_t">Stephanopoulos DE, Monge R, Schell KH, et al. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med 1998; 26:1744.</a></li><li><a class="nounderline abstract_t">Wheeler DS, Jacobs BR, Kenreigh CA, et al. Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. Pediatr Crit Care Med 2005; 6:142.</a></li><li><a class="nounderline abstract_t">Mitra A, Bassler D, Goodman K, et al. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev 2005; :CD001276.</a></li><li><a class="nounderline abstract_t">Dalabih A, Harris ZL, Bondi SA, Arnold DH. Contemporary aminophylline use for status asthmaticus in pediatric ICUs. Chest 2012; 141:1122.</a></li><li><a class="nounderline abstract_t">Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349:301.</a></li><li><a class="nounderline abstract_t">Bohn D, Kalloghlian A, Jenkins J, et al. Intravenous salbutamol in the treatment of status asthmaticus in children. Crit Care Med 1984; 12:892.</a></li><li><a class="nounderline abstract_t">Fortenberry JD, Del Toro J, Jefferson LS, et al. Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure (BiPAP) nasal mask ventilation. Chest 1995; 108:1059.</a></li><li><a class="nounderline abstract_t">Padman R, Lawless ST, Kettrick RG. Noninvasive ventilation via bilevel positive airway pressure support in pediatric practice. Crit Care Med 1998; 26:169.</a></li><li><a class="nounderline abstract_t">Bernet V, Hug MI, Frey B. Predictive factors for the success of noninvasive mask ventilation in infants and children with acute respiratory failure. Pediatr Crit Care Med 2005; 6:660.</a></li><li><a class="nounderline abstract_t">Essouri S, Chevret L, Durand P, et al. Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. Pediatr Crit Care Med 2006; 7:329.</a></li><li><a class="nounderline abstract_t">Piastra M, Conti G, Caresta E, et al. Noninvasive ventilation options in pediatric myasthenia gravis. Paediatr Anaesth 2005; 15:699.</a></li><li><a class="nounderline abstract_t">Sprague K, Graff G, Tobias DJ. Noninvasive ventilation in respiratory failure due to cystic fibrosis. South Med J 2000; 93:954.</a></li><li><a class="nounderline abstract_t">Carroll CL, Schramm CM. Noninvasive positive pressure ventilation for the treatment of status asthmaticus in children. Ann Allergy Asthma Immunol 2006; 96:454.</a></li><li><a class="nounderline abstract_t">Akingbola OA, Simakajornboon N, Hadley Jr EF, Hopkins RL. Noninvasive positive-pressure ventilation in pediatric status asthmaticus. Pediatr Crit Care Med 2002; 3:181.</a></li><li><a class="nounderline abstract_t">Thill PJ, McGuire JK, Baden HP, et al. Noninvasive positive-pressure ventilation in children with lower airway obstruction. Pediatr Crit Care Med 2004; 5:337.</a></li><li><a class="nounderline abstract_t">Beers SL, Abramo TJ, Bracken A, Wiebe RA. Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics. Am J Emerg Med 2007; 25:6.</a></li><li><a class="nounderline abstract_t">Javouhey E, Barats A, Richard N, et al. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis. Intensive Care Med 2008; 34:1608.</a></li><li><a class="nounderline abstract_t">Cambonie G, Milési C, Jaber S, et al. Nasal continuous positive airway pressure decreases respiratory muscles overload in young infants with severe acute viral bronchiolitis. Intensive Care Med 2008; 34:1865.</a></li><li><a class="nounderline abstract_t">Mayordomo-Colunga J, Medina A, Rey C, et al. Non-invasive ventilation in pediatric status asthmaticus: a prospective observational study. Pediatr Pulmonol 2011; 46:949.</a></li><li><a class="nounderline abstract_t">Najaf-Zadeh A, Leclerc F. Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review. Ann Intensive Care 2011; 1:15.</a></li><li><a class="nounderline abstract_t">Korang SK, Feinberg J, Wetterslev J, Jakobsen JC. Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database Syst Rev 2016; 9:CD012067.</a></li><li><a class="nounderline abstract_t">Basnet S, Mander G, Andoh J, et al. Safety, efficacy, and tolerability of early initiation of noninvasive positive pressure ventilation in pediatric patients admitted with status asthmaticus: a pilot study. Pediatr Crit Care Med 2012; 13:393.</a></li><li><a class="nounderline abstract_t">Needleman J, Sykes J, Schroeder S, Singer L. Noninvasive positive pressure ventilation in the treatment of pediatric status asthmaticus. Pediatr Asthma Allergy Immunol 2004; 17:272.</a></li><li><a class="nounderline abstract_t">Abstracts of the 33rd International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium. March 19-22, 2013. Crit Care 2013; 17 Suppl 2:P1.</a></li><li><a class="nounderline abstract_t">Baudin F, Buisson A, Vanel B, et al. Nasal high flow in management of children with status asthmaticus: a retrospective observational study. Ann Intensive Care 2017; 7:55.</a></li><li><a class="nounderline abstract_t">Pilar J, Modesto I Alapont V, Lopez-Fernandez YM, et al. High-flow nasal cannula therapy versus non-invasive ventilation in children with severe acute asthma exacerbation: An observational cohort study. Med Intensiva 2017; 41:418.</a></li><li><a class="nounderline abstract_t">Carroll CL. Heliox for children with acute asthma: has the sun set on this therapy? Pediatr Crit Care Med 2010; 11:428.</a></li><li><a class="nounderline abstract_t">Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics 2005; 116:1127.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Castro-Rodriguez JA. Heliox-driven β2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014; 112:29.</a></li><li><a class="nounderline abstract_t">Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:633.</a></li></ol></div><div id="topicVersionRevision">Topic 5747 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12420904" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Surveillance for asthma--United States, 1980-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876177" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in admissions for pediatric status asthmaticus in New Jersey over a 15-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414819" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629678" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute asthma in the pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798903" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798903" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182663" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Assessment and treatment of acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4021061" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Physiologic and psychological characteristics associated with deaths due to asthma in childhood. A case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577516" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Determinants of management errors in acute severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579156" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preventable factors in hospital admissions for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536336" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Variations in asthma hospitalizations and deaths in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540482" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes following admission to intensive care for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25323234" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Medication adherence and the risk of severe asthma exacerbations: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32084098" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32084098" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Standardized Protocol Is Associated With a Decrease in Continuous Albuterol Use and Length of Stay in Critical Status Asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628833" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Corticosteroid therapy in critically ill pediatric asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29660840" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116362" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25080126" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990919" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute severe asthma: differences in therapies and outcomes among pediatric intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781734" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Continuous intravenous terbutaline for pediatric status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730599" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846615" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474160" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Contemporary aminophylline use for status asthmaticus in pediatric ICUs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024371" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomised trial of intravenous salbutamol in early management of acute severe asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435957" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous salbutamol in the treatment of status asthmaticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555120" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure (BiPAP) nasal mask ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428561" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Noninvasive ventilation via bilevel positive airway pressure support in pediatric practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16276332" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictive factors for the success of noninvasive mask ventilation in infants and children with acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738493" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029407" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Noninvasive ventilation options in pediatric myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11147476" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Noninvasive ventilation in respiratory failure due to cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597080" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Noninvasive positive pressure ventilation for the treatment of status asthmaticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780991" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Noninvasive positive-pressure ventilation in pediatric status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215002" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Noninvasive positive-pressure ventilation in children with lower airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157675" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18500424" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18607564" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nasal continuous positive airway pressure decreases respiratory muscles overload in young infants with severe acute viral bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520437" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Non-invasive ventilation in pediatric status asthmaticus: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906346" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27687114" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Non-invasive positive pressure ventilation for acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067982" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety, efficacy, and tolerability of early initiation of noninvasive positive pressure ventilation in pediatric patients admitted with status asthmaticus: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Noninvasive positive pressure ventilation in the treatment of pediatric status asthmaticus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530473" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Abstracts of the 33rd International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium. March 19-22, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28534235" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nasal high flow in management of children with status asthmaticus: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28216104" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : High-flow nasal cannula therapy versus non-invasive ventilation in children with severe acute asthma exacerbation: An observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453617" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Heliox for children with acute asthma: has the sun set on this therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263999" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24331390" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Heliox-drivenβ2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778163" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mortality in patients hospitalized for asthma exacerbations in the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
